Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1990;39(4):345-8.
doi: 10.1007/BF00315407.

Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure

H Spahn  1 , H Knauf, E Mutschler
Affiliations
Clinical Trial

Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure

H Spahn et al. Eur J Clin Pharmacol. 1990.

Abstract

The pharmacokinetics of 20 mg torasemide i.v. has been studied in 7 healthy controls and 9 patients with varying degrees of renal impairment. Torasemide had a t1/2 of about 4h which was independent of kidney function, as the nonrenal clearance of torasemide was 3-times greater than its renal clearance. The active metabolite M 1 and the main metabolite M 5 were accumulated in chronic renal failure. In contrast to liver function, therefore, kidney failure does not have an important effect on the pharmacokinetics of torasemide.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eur J Clin Pharmacol. 1990;39(4):337-43 - PubMed
    1. Eur J Clin Pharmacol. 1986;31 Suppl:49-51 - PubMed
    1. Clin Pharmacol Ther. 1980 Oct;28(4):449-55 - PubMed
    1. Arzneimittelforschung. 1988 Jan;38(1A):164-6 - PubMed
    1. Arzneimittelforschung. 1988 Jan;38(1A):176-9 - PubMed

LinkOut - more resources